David E Avigan

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Dendritic cells: development, function and potential use for cancer immunotherapy
    D Avigan
    Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Blood Rev 13:51-64. 1999
  2. doi request reprint Dendritic/tumor fusion cells as cancer vaccines
    David Avigan
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Semin Oncol 39:287-95. 2012
  3. pmc Dendritic cell defects in patients with cancer: mechanisms and significance
    Corrine Lenahan
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    Breast Cancer Res 8:101. 2006
  4. ncbi request reprint Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma
    David E Avigan
    Beth Israel Deaconess Medical Center and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    J Immunother 30:749-61. 2007
  5. ncbi request reprint Dendritic cell/tumour fusions vaccine
    D Avigan
    Bone Marrow Transplantation and Hematological Malignancies, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Dev Biol (Basel) 116:161-8; discussion 179-86. 2004
  6. ncbi request reprint Selective in vivo mobilization with granulocyte macrophage colony-stimulating factor (GM-CSF)/granulocyte-CSF as compared to G-CSF alone of dendritic cell progenitors from peripheral blood progenitor cells in patients with advanced breast cancer undergoin
    D Avigan
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Cancer Res 5:2735-41. 1999
  7. pmc Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
    Paul G Richardson
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 116:679-86. 2010
  8. pmc The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation
    Su Jung Song
    Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, MA 02215, USA
    Cell Stem Cell 13:87-101. 2013
  9. pmc A PML–PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance
    Keisuke Ito
    Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, Massachusetts, USA
    Nat Med 18:1350-8. 2012
  10. pmc Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma
    Paul G Richardson
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 27:5713-9. 2009

Detail Information

Publications27

  1. ncbi request reprint Dendritic cells: development, function and potential use for cancer immunotherapy
    D Avigan
    Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Blood Rev 13:51-64. 1999
    ..Incorporating the expanding knowledge of dendritic cell biology into vaccine design is essential for the generation of effective immunotherapy for cancer patients...
  2. doi request reprint Dendritic/tumor fusion cells as cancer vaccines
    David Avigan
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Semin Oncol 39:287-95. 2012
    ..A current focus of research interest lies in enhancing response to cancer vaccines, by combining vaccination with tumor cytoreduction, regulatory T-cell depletion, and blockade of critical inhibitory pathways...
  3. pmc Dendritic cell defects in patients with cancer: mechanisms and significance
    Corrine Lenahan
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    Breast Cancer Res 8:101. 2006
    ..In vitro studies suggest that a soluble factor secreted by breast cancer cells is responsible for this phenomenon. In contrast, ex vivo conditioning of DCs with CD-40 ligand and IL-12 was protective against tumor-induced apoptosis...
  4. ncbi request reprint Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma
    David E Avigan
    Beth Israel Deaconess Medical Center and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    J Immunother 30:749-61. 2007
    ..Vaccination of patients with RCC with allogeneic DC/tumor fusions was feasible, well tolerated, and resulted in immunologic and clinical responses in a subset of patients...
  5. ncbi request reprint Dendritic cell/tumour fusions vaccine
    D Avigan
    Bone Marrow Transplantation and Hematological Malignancies, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Dev Biol (Basel) 116:161-8; discussion 179-86. 2004
  6. ncbi request reprint Selective in vivo mobilization with granulocyte macrophage colony-stimulating factor (GM-CSF)/granulocyte-CSF as compared to G-CSF alone of dendritic cell progenitors from peripheral blood progenitor cells in patients with advanced breast cancer undergoin
    D Avigan
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Cancer Res 5:2735-41. 1999
    ..The addition of GM-CSF to the mobilization regimen resulted in greater yields of functionally active DCs for potential use in posttransplant immunotherapy...
  7. pmc Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
    Paul G Richardson
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 116:679-86. 2010
    ..Lenalidomide-bortezomib-dexamethasone demonstrates favorable tolerability and is highly effective in the treatment of newly diagnosed myeloma. This study is registered at http://clinicaltrials.gov as NCT00378105...
  8. pmc The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation
    Su Jung Song
    Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, MA 02215, USA
    Cell Stem Cell 13:87-101. 2013
    ..Our results therefore identify miR-22 as a potent proto-oncogene and suggest that aberrations in the miR-22/TET2 regulatory network are common in hematopoietic malignancies. ..
  9. pmc A PML–PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance
    Keisuke Ito
    Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, Massachusetts, USA
    Nat Med 18:1350-8. 2012
    ..Thus, our findings identify a metabolic switch for the control of HSC cell fate with potential therapeutic implications...
  10. pmc Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma
    Paul G Richardson
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 27:5713-9. 2009
    ..This phase I, dose-escalation study (ie, NCT00153933) evaluated safety and determined the maximum-tolerated dose (MTD) of lenalidomide plus bortezomib in patients with relapsed or with relapsed and refractory MM...
  11. ncbi request reprint A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer
    A D Elias
    Harvard Medical School, and Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    Bone Marrow Transplant 27:269-78. 2001
    ..Whilst selection biases may in part contribute to this effect, a much larger phase II double transplant trial is warranted in preparation for a potential randomized comparison of standard therapy vs single vs double transplant...
  12. ncbi request reprint Innovations and challenges in renal cancer: consensus statement from the first international conference
    Michael B Atkins
    Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Cancer Res 10:6277S-81S. 2004
  13. ncbi request reprint Detection of Staphylococcus aureus in peripheral blood stem cell cultures after sterilization of standard blood cultures
    Mitchell J Schwaber
    Department of Medicine, Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Clin Apher 18:37-9. 2003
    ..Cultures of apheresis product may be more sensitive to the presence of bacteremia than standard blood cultures, and they should guide clinical decisions when the bacteria isolated are potential pathogens or suggest clinical infection...
  14. doi request reprint Immunomodulatory effects of vitamin D: implications for GVHD
    J Rosenblatt
    Division of Hematology Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Bone Marrow Transplant 45:1463-8. 2010
    ..These data suggest that exposure to vitamin D results in immature DC populations that bias toward tolerizing rather than stimulatory T-cell populations. Vitamin D may therefore have a role in the prevention of GVHD...
  15. ncbi request reprint Rituximab and ifosfamide, mitoxantrone, etoposide (RIME) with Neupogen support for B-cell non-Hodgkin's lymphoma prior to high-dose chemotherapy with autologous haematopoietic transplant
    R M Joyce
    Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
    Eur J Haematol Suppl 64:56-62. 2001
    ..Haematological toxicity was manageable with filgrastim, there were some infectious complications...
  16. ncbi request reprint The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farbe
    A D Elias
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Biol Blood Marrow Transplant 8:198-205. 2002
    ..Although selection biases may have in part contributed to this effect, a randomized comparison of standard therapy versus short induction/double transplantation is warranted...
  17. ncbi request reprint Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity
    J Gong
    Dana Farber Cancer Institute, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    J Immunol 165:1705-11. 2000
    ..These findings demonstrate that fusions of ovarian carcinoma cells and DC activate T cell responses against autologous tumor and that the fusions are functional when generated with either autologous or allogeneic DC...
  18. ncbi request reprint A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase I/II studies
    A D Elias
    Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Bone Marrow Transplant 28:447-54. 2001
    ..Whilst selection biases may in part contribute to favorable EFS and OS, a randomized comparison of standard therapy vs double transplant in both metastatic and locally advanced breast cancer is warranted...
  19. ncbi request reprint Vaccination against infectious disease following hematopoietic stem cell transplantation
    D Avigan
    Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Biol Blood Marrow Transplant 7:171-83. 2001
    ..Strategies to enhance vaccine efficacy include pretransplantation immunization of the stem cell donor and the use of cytokine adjuvants...
  20. ncbi request reprint A phase I-II study of rituximab, ifosfamide, mitoxantrone and etoposide (R-IME) for B cell non-Hodgkin's lymphoma prior to and after high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT)
    R M Joyce
    Harvard Medical School, Boston, MA, USA
    Ann Oncol 14:i21-7. 2003
    ..R-IME is an effective cytoreductive and mobilization regimen. There appears to be a reduction in the number of lymphoma cells in the stem cell product and the toxicity is manageable...
  21. ncbi request reprint A major fraction of human bone marrow lymphocytes are Th2-like CD1d-reactive T cells that can suppress mixed lymphocyte responses
    M A Exley
    Cancer Biology Program, Hematology Oncology, Beth Israel Deaconess Medical Center, Bone Marrow Transplant Program, Harvard Skin Disease Research Center, Harvard Medical School, Boston, MA 02115, USA
    J Immunol 167:5531-4. 2001
    ..Distinct CD1d-reactive T cell populations have the potential to suppress graft-vs-host disease and stimulate antitumor responses...
  22. pmc Peripheral blood progenitor cell product contains Th1-biased noninvariant CD1d-reactive natural killer T cells: implications for posttransplant survival
    Angela Shaulov
    Department of Hematology Oncology Beth Israel Deaconess Medical Center, Boston, Mass 02215, USA
    Exp Hematol 36:464-72. 2008
    ..Recent data suggests that NKT might contribute to clinical benefits of PBPC...
  23. pmc PML targeting eradicates quiescent leukaemia-initiating cells
    Keisuke Ito
    Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Department of Medicine, Harvard Medical School, New Research Building, 330 Brookline Avenue, Boston, Massachusetts 02215, USA
    Nature 453:1072-8. 2008
    ....
  24. pmc Interleukin-2 and regulatory T cells in graft-versus-host disease
    John Koreth
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, MA 02215, USA
    N Engl J Med 365:2055-66. 2011
    ..Interleukin-2 is critical for Treg cell growth, survival, and activity. We hypothesized that low-dose interleukin-2 could preferentially enhance Treg cells in vivo and suppress clinical manifestations of chronic GVHD...
  25. pmc Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial
    Paul G Richardson
    Department of Adult Oncology, Harvard Medical School, Boston, MA, USA
    Biol Blood Marrow Transplant 16:1005-17. 2010
    ..In the absence of any differences in activity, toxicity or changes in PAI-1 level, defibrotide 25 mg/kg/day was selected for ongoing phase III trials in VOD...
  26. pmc Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy
    Paul G Richardson
    Dana Farber Cancer Institute, 44 Binney St, Dana 1B02, Boston, MA 02115, USA
    J Clin Oncol 27:3518-25. 2009
    ..Baseline myeloma-associated neuropathy seems more common than previously reported, and bortezomib-associated neuropathy, although a common toxicity, is reversible in most patients...
  27. doi request reprint Incidence of contrast-induced nephropathy in patients with multiple myeloma undergoing contrast-enhanced CT
    Jay K Pahade
    Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    AJR Am J Roentgenol 196:1094-101. 2011
    ....